Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.

Scientific reports - 28 Oct 2023

Fekete Ferenc, Menus Ádám, Tóth Katalin, Kiss Ádám Ferenc, Minus Annamária, Sirok Dávid, Belič Aleš, Póti Ádám, Csukly Gábor, Monostory Katalin

Abstract excerpt

Olanzapine is a commonly prescribed atypical antipsychotic agent for treatment of patients with schizophrenia and bipolar disorders. Previous in vitro studies using human liver microsomes identified CYP1A2 and CYP2D6 enzymes being responsible for CYP-mediated metabolism of olanzapine. The present work focused on the impact of CYP1A2 and CYP2D6 genetic polymorphisms as well as of CYP1A2 metabolizing capacity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP1A2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Olanzapine

Share to Pharmacogenetics and Drug Metabolism

Share to RNA, Messenger

Share to Schizophrenia research and treatment

Source

Open in PubMed Open full text

Identifiers

PMID: 37898643
DOI: 10.1038/s41598-023-45752-6
PMCID: PMC10613299

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP1A2 expression rather than genotype is associated with olanzapine concentration in psychiatric patients.PMID 37898643Read ↗

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Semantic proximity Read ↗

Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.Semantic proximity Read ↗

Pharmacogenetics of Olanzapine MetabolismSemantic proximity Read ↗

Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.Semantic proximity Read ↗

CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations.Semantic proximity Read ↗

The pharmacogenetics of treatment with olanzapineSemantic proximity Read ↗

Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure.Semantic proximity Read ↗

Impact of CYP1A2 genetic polymorphisms on pharmacokinetics of antipsychotic drugs: a systematic review and meta-analysis.Semantic proximity Read ↗

Interindividual Variability in Olanzapine Steady-State Concentrations in Chinese: Exploring Single Nucleotide Polymorphisms of Metabolic EnzymesSemantic proximity Read ↗

The Potential Role of POR*28 and CYP1A2*F Genetic Variations and Lifestyle Factors on Clozapine and N-DesmethylClozapine Plasma Levels in Schizophrenia Patients.Semantic proximity Read ↗

Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes.Semantic proximity Read ↗

Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.